Japanese Journal of Cancer and Chemotherapy最新文献_第4页

[Two Cases of Peritoneal Dissemination after Resection for Breast Cancer]. 乳腺癌切除术后腹膜播散2例

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Tomoharu Ishiyama, Akira Jingu, Hidekazu Matsumoto

引用次数: 0

[A Case of Chemotherapy-Associated Thrombosis during Neoadjuvant Chemotherapy for Breast Cancer]. 【乳腺癌新辅助化疗中化疗相关血栓1例】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Rika Matsusaka, Hirotoshi Takahashi, Kazuya Miyoshi

引用次数: 0

[Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)]. [针对非g12c KRAS突变的治疗方法的发展（重点是G12D和Pan-RAS）]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Shoichi Itoh, Miyako Satouchi

{"title":"[Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)].","authors":"Shoichi Itoh, Miyako Satouchi","doi":"","DOIUrl":"","url":null,"abstract":"Sotorasib and adagrasib, which are KRAS G12C inhibitors, have shown favorable clinical results mainly in non-small cell lung cancer (NSCLC) and have already been introduced into clinical practice. However, for patients with non-G12C mutations that account for the majority, such as G12D, G12V, and G13D, effective targeted therapies have still not been established. Setidegrasib (ASP3082) is a first-in-class proteolysis-targeting chimera molecule (PROTAC) that targets the KRAS G12D mutation. Phase Ⅰ trial targeting previously treated patients with advanced solid tumors harboring KRAS G12D mutations has been initiated, and the latest results were reported in the N Engl J Med in March 2026. Daraxonrasib (RMC-6236) is a pan-RAS inhibitor that targets all ON-state RAS (KRAS, NRAS, HRAS) by forming a specific pocket spanning the Switch Ⅰand Switch Ⅱ regions of KRAS through a mechanism called tri-complex/molecular glue. Currently, multiple international collaborative phase Ⅲ trials on RMC-6236, mainly focusing on PDAC and NSCLC, are underway. The development of new drugs targeting molecules other than KRAS G12C is progressing rapidly, and in KRAS mutation-positive solid cancers where prognosis was difficult to improve with conventional chemotherapy, there is a high possibility that the existing standard treatments will be significantly revised.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 7","pages":"441-447"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions]. [靶向KRAS G12C突变的治疗策略-现状和未来方向]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Shinji Nakamichi, Kaoru Kubota

{"title":"[Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].","authors":"Shinji Nakamichi, Kaoru Kubota","doi":"","DOIUrl":"","url":null,"abstract":"KRAS G12C has emerged as a clinically important therapeutic target in non-small cell lung cancer (NSCLC), representing a major advance in the treatment of KRAS-driven malignancies. The development of covalent inhibitors targeting the switch-Ⅱ pocket of inactive, GDP-bound KRAS has transformed a previously undruggable oncogene into a molecularly actionable target. First-generation KRAS G12C inhibitors, including sotorasib and adagrasib, have demonstrated clinically meaningful activity in previously treated NSCLC; however, their benefit is limited by acquired resistance, which arises through secondary KRAS alterations, bypass pathway activation, and adaptive reactivation of downstream MAPK signaling. In addition, treatment-related hepatotoxicity, particularly in the setting of prior or closely sequenced immune checkpoint inhibitor exposure, has emerged as an important clinical concern. Multiple next-generation KRAS G12C inhibitors, such as divarasib, glecirasib, and olomorasib, are currently under clinical development, with early evidence suggesting improved potency, selectivity, and tolerability. Furthermore, combination strategies incorporating immune checkpoint inhibitors and upstream or downstream pathway-targeted agents, including SHP2, SOS1, and MEK inhibitors, are being actively investigated to enhance the depth and durability of response. More recently, the advent of RAS (ON) inhibitors, exemplified by daraxonrasib (RMC-6236), has introduced a distinct therapeutic paradigm by directly targeting active RAS through a tri-complex mechanism. As the therapeutic landscape continues to evolve, optimal treatment selection will require integrated consideration of molecular heterogeneity, resistance mechanisms, toxicity profiles, and patient-centered shared decision-making.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 7","pages":"435-440"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Adenocarcinoma of Esophagogastric Junction with CY1 in Which Staging Laparoscopy Was Useful in Deciding Whether to Continue Chemotherapy]. [1例食管胃交界处腺癌伴CY1，腹腔镜分期判断是否继续化疗]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Kiyoshi Kawaguchi, Hiroto Fujimoto, Hideki Isobe, Masahiro Urayama, Kenichi Shibata, Ryo Nakano, Keiji Ohta

引用次数: 0

[Comparison of Cisplatin plus Etoposide and Carboplatin plus Etoposide in Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer-A Single-Institution Retrospective Study]. 顺铂加依托泊苷与卡铂加依托泊苷在有限期小细胞肺癌放化疗中的比较——单机构回顾性研究。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-07-01

Yuki Fukunishi, Yukihiro Nakamura, Takahiro Yagi, Ren Seike, Taisuke Kikuchi, Eiji Sugimoto, Yoshihiro Taguchi, Takahide Kato, Shoichiro Yamamoto, Hiroshi Ohnishi, Naoyuki Nogami, Osamu Yamaguchi

{"title":"[Comparison of Cisplatin plus Etoposide and Carboplatin plus Etoposide in Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer-A Single-Institution Retrospective Study].","authors":"Yuki Fukunishi, Yukihiro Nakamura, Takahiro Yagi, Ren Seike, Taisuke Kikuchi, Eiji Sugimoto, Yoshihiro Taguchi, Takahide Kato, Shoichiro Yamamoto, Hiroshi Ohnishi, Naoyuki Nogami, Osamu Yamaguchi","doi":"","DOIUrl":"","url":null,"abstract":"Background: The Japanese Guidelines for Diagnosis and Treatment of Lung Cancer recommend concurrent chemoradiotherapy (CRT) with cisplatin plus etoposide (PE) for limited-stage small cell lung cancer (LS-SCLC). When cisplatin administration is difficult, carboplatin plus etoposide (CE) with either sequential or concurrent thoracic radiotherapy is selected. While overseas studies have shown no significant difference in overall survival between PE and CE, evidence in Japan remains limited.Methods: We retrospectively compared progression-free survival (PFS) between patients treated with PE and those treated with CE among LS-SCLC cases that received CRT between March 2005 and March 2025.Results: A total of 43 patients were included (PE: 24, CE: 19). Most CE patients (89.5%) received CBDCA (AUC5) plus ETP (80 mg/m2). The median PFS was 13.5 months for PE (95%CI: 10.0-NA) and 9.9 months for CE (95%CI: 6.8-NA) (p = 0.369). The adjusted hazard ratio for PE versus CE was 0.85 (95% CI: 0.37-1.97; p = 0.702). The incidence of grade ≥3 neutropenia was 95.8% in PE and 89.5% in CE (p = 0.575), whereas febrile neutropenia occurred in 50.0% and 15.8% of patients, respectively (p = 0.026).Conclusion: In this retrospective study of patients with LS-SCLC treated with CRT, no clear differences in PFS or OS were observed between the PE and CE regimens.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 7","pages":"454-458"},"PeriodicalIF":0.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Outcome of Eight-Year-Experiences of BCG Intravesical Instillation Therapy in Patients with Non-Muscle Invasive Bladder Cancer in Asahikawa Medical University Hospital]. 【朝日医科大学医院膀胱内灌注BCG治疗非肌性浸润性膀胱癌8年疗效观察】。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-06-01

Junichi Hori, Masayuki Tokumitsu, Satoshi Yamaguchi, Hironori Ishida, Miyu Otani, Shin Kobayashi, Naoki Wada, Hidehiro Kakizaki, Kazuyuki Numakura

{"title":"[Outcome of Eight-Year-Experiences of BCG Intravesical Instillation Therapy in Patients with Non-Muscle Invasive Bladder Cancer in Asahikawa Medical University Hospital].","authors":"Junichi Hori, Masayuki Tokumitsu, Satoshi Yamaguchi, Hironori Ishida, Miyu Otani, Shin Kobayashi, Naoki Wada, Hidehiro Kakizaki, Kazuyuki Numakura","doi":"","DOIUrl":"","url":null,"abstract":"We retrospectively investigated the outcome of BCG intravesical instillation therapy for patients with non-muscle invasive bladder cancer. From 2011 to 2019, a total of 79 patients had received BCG intravesical instillation therapy for non-muscle invasive bladder cancer. Of these 79 patients, 62 were included in this study. The protocol of BCG intravesical instillation therapy was as follows: instillation once per week for 6 consecutive weeks as induction, followed by instillation twice (once per week for 2 consecutive weeks) at each of 4, 6 and 12 months after TUR-BT as maintenance. BCG completion rate was 42%. The most frequent reasons for BCG discontinuation were adverse events of BCG treatment (70%). Two-year bladder non-recurrence survival was 72%. BCG completion group showed a statistically significant better bladder non-recurrence survival compared to BCG non-completion group. However, when we focused on the patients who discontinued BCG treatment only due to adverse events, bladder non-recurrence survival in this patient group was not different from BCG completion group. In conclusion, adverse events resulting in discontinuation of BCG treatment seem to be a prognostic factor for the efficacy of BCG treatment. But from the perspective of patient's quality of life, a better management is required to prevent adverse events of BCG treatment and to promote the BCG completion rate.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 6","pages":"407-412"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Therapeutic Targets by Pathology AI and Spatial Transcriptomics in Breast Cancer]. [病理AI和空间转录组学在乳腺癌中的治疗靶点]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-06-01

Maki Tanioka

{"title":"[Therapeutic Targets by Pathology AI and Spatial Transcriptomics in Breast Cancer].","authors":"Maki Tanioka","doi":"","DOIUrl":"","url":null,"abstract":"Recent advances in pathology foundation models have markedly improved the accuracy and generalizability of histopathological image analysis in breast cancer. However, the mechanisms of resistance to CDK4/6 inhibitors in hormone receptor-positive, HER2-negative advanced breast cancer remain incompletely understood. This article outlines a strategy to identify therapeutic targets by integrating pathology AI with spatial transcriptomics. We developed AI-directed spatial transcriptomics (AID-ST), a framework that compares gene expression profiles between drug-sensitive and drug-resistant regions identified by pathology AI. In a preliminary analysis of clinical breast cancer specimens, this approach suggested that KRAS pathway activation is a major driver of resistance, accompanied in part by Polycomb dysregulation, RB loss, PI3K pathway alteration, and acquisition of stem-like features. Additional spatial analyses of paired pre- and post-treatment specimens supported these findings and further suggested a role for the tumor microenvironment, including EMT- and IL6/JAK/STAT3-related changes, in promoting resistant phenotypes. These results indicate that integrating pathology AI with spatial transcriptomics may enable systematic classification of resistance subtypes and prioritization of actionable therapeutic targets in breast cancer.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 6","pages":"379-384"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[AI in Cancer Pathology-Present Developments and Future Directions for Treatment Optimization]. [癌症病理学中的人工智能-目前的发展和治疗优化的未来方向]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-06-01

Maki Takao, Daisuke Komura, Shumpei Ishikawa

{"title":"[AI in Cancer Pathology-Present Developments and Future Directions for Treatment Optimization].","authors":"Maki Takao, Daisuke Komura, Shumpei Ishikawa","doi":"","DOIUrl":"","url":null,"abstract":"Recent advances in artificial intelligence (AI) technologies have substantially expanded the role of pathological image analysis beyond improvements in diagnostic accuracy and efficiency. These developments now enable the integration of histopathological images with non-image data, prediction of treatment response and prognosis, and reduction of the workload for medical professionals. In this review, we provide an overview of representative analytical methods for pathological images, as well as approaches for predicting biomarkers and therapeutic responsiveness directly from histological images. We summarize key studies across major cancer types, pan-cancer investigations, and examples that have been successfully implemented in clinical practice. Additionally, we introduce emerging frameworks such as quantitative analysis of cellular components and tumor microenvironments, pathology foundation models, mRNA expression-based treatment response prediction, integration with spatial transcriptomics data, and applications in clinical trial design. Despite this progress, several challenges remain, such as limited availability of large-scale, high-quality datasets, domain shift across institutions, lack of model interpretability, potential biases, and significant barriers to clinical implementation and regulatory approval. Nevertheless, future developments are expected to enable the simultaneous estimation of multiple biomarkers from a single pathological image, potentially eliminating the need for additional tests. Ultimately, such advances may facilitate rapid, patient-specific drug selection and contribute to more efficient and personalized cancer treatment.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 6","pages":"385-397"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Cancer Diagnosis Support System Using 3D Image Recognition AI]. [基于3D图像识别AI的癌症诊断支持系统]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-06-01

Kenichi Morooka

引用次数: 0